News | October 20, 2021
AstraZeneca India opens clinical data and insights division
The division is expected to grow to over a 100-member strong team by 2022
The division is expected to grow to over a 100-member strong team by 2022
It is the first presbyopia-correcting lens implant for cataract surgery
The company claims that its Empagliflozin tablets are the most affordable in India
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
The consortium envisages carrying out surveillance of important bacterial, viral and parasitic infections of zoonotic as well as transboundary pathogens
Since its inception, the company has either acquired or taken a majority stake in five companies
This opens up a huge market for the company’s Magnezis implants in India
The start-up claims in clinical trials over 90 % achieved type 2 diabetes reversal and 92 % eliminated all diabetes medication within 90 days of joining the twin service
_256_384.jpg)
In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report
Subscribe To Our Newsletter & Stay Updated
